Torrent Pharmaceuticals
Torrent Pharmaceuticals is an Indian multinational pharmaceutical company and a member of the Torrent Group.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Torrent Pharmaceuticals Ltd, also known as Torrent Pharma, is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat, and operating as part of the Torrent Group. The company traces its origins to 1959, when U. N. Mehta established it under the name Trinity Laboratories. It adopted the Torrent Pharmaceuticals name in 1971, marking the development of the business into the pharmaceutical company associated with the Torrent Group today. The company develops, manufactures, and markets medicines across a broad range of therapeutic categories. Its principal areas of activity include cardiovascular medicine, central nervous system treatments, gastrointestinal products, diabetology, anti-infective medicines, and pain-management products. It also participates in nephrology, oncology, gynecology, respiratory care, and pediatrics. This portfolio gives Torrent Pharma exposure to both chronic-care and acute-care treatment areas, with particular relevance to long-term conditions such as cardiovascular disease, diabetes, and disorders of the central nervous system. Torrent Pharma has built an international presence through product registrations, manufacturing and commercial activities, acquisitions, and partnerships. Reference material describes the company as operating in more than 40 countries and having more than 2,000 product registrations globally. Its international expansion included the creation of a 50:50 sales joint venture with Sanofi in 1997. Torrent later exited that arrangement in 2002 by selling its stake to Sanofi. Acquisitions have been an important part of the company's growth strategy. In 2005, Torrent acquired Heumann Pharma Generics GmbH in Germany from Pfizer. In India, it acquired the formulations business of Elder Pharmaceuticals in 2013 and the domestic business of Unichem Laboratories in 2017. The latter transaction significantly expanded Torrent's domestic product portfolio and commercial footprint. In 2022, the company entered the skincare segment more substantially through its acquisition of Curatio Healthcare, a skincare manufacturer. The company has also faced product-quality and regulatory challenges. In 2018, it recalled certain valsartan- and losartan-containing tablets after contamination concerns involving probable carcinogenic nitrosamine compounds. In September 2019, the United States Food and Drug Administration announced another losartan recall involving batches containing N-methylnitrosobutyric acid above the agency's acceptable daily intake level. These events illustrate the regulatory and manufacturing-control obligations associated with supplying medicines across multiple markets. Torrent Pharmaceuticals is therefore best understood as an Indian multinational drug company rather than a consumer-goods or housewares brand. Its business model combines branded and generic pharmaceutical activity, therapeutic-area breadth, international registrations, and expansion through acquisitions. The available reference material does not establish a current chief executive, detailed ownership structure, official website URL, stock ticker, or current financial figures, so those fields are left unspecified.
History
Torrent Pharmaceuticals began in 1959, when U. N. Mehta established a pharmaceutical business called Trinity Laboratories. The company retained that name during its initial period of development and was renamed Torrent Pharmaceuticals in 1971. The change connected the operating company more directly with the Torrent identity and preceded its later expansion into a broad, internationally oriented pharmaceutical enterprise within the Torrent Group. A significant early international commercial step came in 1997, when Torrent Pharma and Sanofi formed Sanofi Torrent, a 50:50 joint venture intended to sell Torrent Pharma products. The partnership provided a route for commercial distribution and collaboration with a major international pharmaceutical company. Torrent subsequently withdrew from the joint venture in 2002 by selling its stake to Sanofi. The company pursued inorganic growth in Europe in 2005 by acquiring Heumann Pharma Generics GmbH, a German pharmaceutical business that had been owned by Pfizer. The transaction strengthened Torrent's presence in generic pharmaceuticals and broadened its international platform. Torrent later concentrated on expanding its Indian formulations business. In 2013, it acquired the India formulations business of Elder Pharmaceuticals for ₹2,004 crore. The transaction added products and commercial capabilities in the Indian market. In 2017, Torrent acquired the domestic business of Unichem Laboratories for ₹3,600 crore, another major portfolio and domestic-market expansion. The company's therapeutic scope has included cardiovascular, central nervous system, gastrointestinal, diabetes, anti-infective, and pain-management medicines. It has also developed activities in nephrology, oncology, gynecology, respiratory care, and pediatrics. The breadth of these categories reflects a business combining chronic-care treatments with products for acute and specialist medical needs. Reference material states that Torrent operates in more than 40 countries and has more than 2,000 product registrations worldwide. In 2022, Torrent expanded into skincare through the acquisition of Curatio Healthcare for ₹2,000 crore. Curatio's skincare focus complemented Torrent's established pharmaceutical portfolio and gave the group a larger presence in dermatology and consumer-facing medical skincare. Quality and regulatory matters have also formed part of the company's documented history. During 2018, Torrent recalled certain valsartan and losartan tablets after the detection of nitrosamine contaminants. N-nitrosodimethylamine and N-nitrosodiethylamine were identified as probable human carcinogens. In September 2019, the United States Food and Drug Administration issued notice of a further losartan recall involving N-methylnitrosobutyric acid above the agency's acceptable daily intake level. These recalls were associated with wider pharmaceutical-industry scrutiny of nitrosamine contamination in medicines containing certain active ingredients. The available material presents Torrent Pharmaceuticals as an active Indian multinational pharmaceutical company whose development has been shaped by renaming, international partnership, overseas acquisition, Indian portfolio consolidation, therapeutic diversification, and skincare expansion. It does not provide sufficient information to identify current executives, current ownership details, a verified official website URL, listing information, or recent financial performance.
- 2022
Curatio Healthcare is acquired
[1]Torrent acquires skincare manufacturer Curatio Healthcare.
- 2019
Further losartan recall
[1]The FDA announces a sixth Torrent losartan recall involving NMBA levels above its acceptable daily intake threshold.
- 2018
Nitrosamine-related tablet recalls
[1]Certain valsartan- and losartan-containing tablets are recalled after nitrosamine contamination is detected.
- 2017
Unichem domestic business is acquired
[1]Torrent acquires the domestic business of Unichem Laboratories.
- 2013
Elder Pharmaceuticals India formulations business is acquired
[1]Torrent acquires Elder Pharmaceuticals' India formulations business.
- 2005
Heumann Pharma Generics is acquired
[1]Torrent acquires the German generic-pharmaceutical company Heumann Pharma Generics GmbH from Pfizer.
- 2002
Torrent exits the Sanofi joint venture
[1]Torrent sells its stake in Sanofi Torrent to Sanofi.
- 1997
Sanofi Torrent joint venture is formed
[1]Torrent Pharma and Sanofi establish a 50:50 joint venture to sell Torrent Pharma products.
- 1971
Company adopts the Torrent Pharmaceuticals name
[1]Trinity Laboratories is renamed Torrent Pharmaceuticals.
- 1959
Trinity Laboratories is established
[1]U. N. Mehta establishes the pharmaceutical business that later becomes Torrent Pharmaceuticals.
Products and positioning
A diversified Indian multinational pharmaceutical company focused on prescription medicines, branded and generic formulations, chronic-care therapies, and international expansion through product registrations, partnerships, and acquisitions.
Therapeutic area
Cardiovascular medicines
Torrent Pharma's cardiovascular portfolio addresses medicines used in the management of heart and circulatory conditions. The reference material identifies cardiovascular therapy as one of the company's principal therapeutic areas, but does not specify individual product names or brands.
Therapeutic area
Central nervous system medicines
The company markets products for central nervous system treatment as part of its core therapeutic portfolio. Available reference material does not provide a verified list of individual medicines, indications, or launch dates.
Therapeutic area
Diabetology products
Diabetology is one of Torrent Pharma's named focus areas, covering medicines used in diabetes care. The supplied sources do not identify specific products or formulations within this category.
Therapeutic area
Gastrointestinal medicines
Torrent Pharma operates in gastrointestinal medicines, forming part of its broad prescription and generic-pharmaceutical offering. Specific brands and product-level details are not established by the supplied reference material.
Dermatology and skincare · 2022
Curatio skincare products
Following its 2022 acquisition of Curatio Healthcare, Torrent Pharma added a skincare-focused business to its broader pharmaceutical portfolio. The available material identifies Curatio as a skincare manufacturer but does not list individual products.
Brand decisions
2022
Acquisition of Curatio HealthcareM&ABackground
Torrent sought to expand its pharmaceutical portfolio into skincare.
Action taken
Torrent acquired skincare manufacturer Curatio Healthcare.
Aftermath
The acquisition increased Torrent's presence in skincare and dermatology-related products.
Acquisition consideration. ₹2,000 crore (2022)
2017
Acquisition of Unichem Laboratories' domestic businessM&ABackground
Torrent continued consolidating and expanding its position in the Indian pharmaceutical market.
Action taken
Torrent acquired Unichem Laboratories' domestic business.
Aftermath
The deal broadened Torrent's domestic product portfolio and market presence.
Acquisition consideration. ₹3,600 crore (2017)
2013
Acquisition of Elder Pharmaceuticals' India formulations businessM&ABackground
Torrent sought to enlarge its Indian formulations portfolio and domestic commercial reach.
Action taken
Torrent acquired Elder Pharmaceuticals' India formulations business.
Aftermath
The transaction added products and operations to Torrent's Indian business.
Acquisition consideration. ₹2,004 crore (2013)
2005
Acquisition of Heumann Pharma GenericsM&ABackground
Torrent pursued international expansion and greater participation in generic pharmaceuticals.
Action taken
Torrent acquired Heumann Pharma Generics GmbH in Germany from Pfizer.
Aftermath
The acquisition expanded Torrent's European generic-pharmaceutical platform.
1997
Formation of Sanofi TorrentM&ABackground
Torrent Pharma sought a collaborative route for selling its products through an international pharmaceutical partner.
Action taken
The company established a 50:50 joint venture with Sanofi.
Aftermath
Torrent exited the venture in 2002 by selling its stake to Sanofi.
Recent events
Torrent Pharmaceuticals reports Q2 and H1 FY2026-27 results[2]
Reported:
Torrent Pharmaceuticals Limited published standalone audited and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/torrent-pharmaceuticals · Editorial policy · How profiles are compiled